Compare General Motors Company (GM) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
General Motors Company vs TG Therapeutics Inc — how do they compare? General Motors Company trades at $82.73 (market cap $72.17B), while TG Therapeutics Inc trades at $55.37 (market cap $8.16B). The key difference: General Motors Company is far larger — about 8.8× TG Therapeutics Inc's market cap, and General Motors Company pays a 0.88% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold General Motors Company for 83 Days and TG Therapeutics Inc for 16 Days on average.
| GM | TGTX | |
|---|---|---|
Market Cap | $72.17B | $8.16B |
Volume | 4,900,304 | 1,735,121 |
Sector | Consumer Cyclical | Health |
52-Week High | $90.30 | $59.06 |
52-Week Low | $55.35 | $26.94 |
Typical Hold Time | 83 Days | 16 Days |
Enterprise Value | $175.15B | $8.37B |
Dividend Yield | 0.88% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
General Motors (GM) trades at $82.73, up 2.15% with a bearish technical signal despite recent earnings beats. The company shows mixed fundamentals with strong operating cash flow of $26.87B in 2025 but declining profit margins. Recent Q3 2026 sales fell 5.5% as EV demand weakens and Toyota challenges GM's U.S. sales leadership. Analyst consensus remains bullish with a $102.08 price target, though technical indicators show resistance at $83-$85 levels.
GM faces near-term headwinds from declining vehicle sales and margin pressure, but cost savings from eased fuel economy rules ($20.4B through 2031) and strong cash generation provide stability. The stock trades at attractive valuations (P/S 0.42) with 67% analyst buy ratings, though competitive threats and EV transition challenges require monitoring for sustained recovery.
TG Therapeutics (TGTX) trades at $55.37, up 4.57% today, but faces a bearish technical signal with recent earnings misses. Strong revenue growth is driven by BRIUMVI, with 2026 guidance raised to $950 million, though profitability is pressured by investments. A shareholder investigation and volatile cash flows add uncertainty, while analyst consensus remains bullish with an $80.50 price target.
The outlook hinges on BRIUMVI's market share gains and subcutaneous formulation progress, offering upside if execution succeeds. Risks include the fiduciary investigation, competitive pressures, and reliance on a single product. The stock presents a high-risk, high-reward opportunity, with current valuation reflecting growth expectations but vulnerable to setbacks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About General Motors Company
General Motors Co. emerged from the bankruptcy of General Motors Corp. (old GM) in July 2009. GM has eight brands and operates under four segments: GM North America, GM International, Cruise, and GM Financial. The United States now has four brands instead of eight under old GM. The company lost its U.S. market share leader crown in 2021 with share down 280 basis points to 14.6%, but we expect GM to reclaim the top spot in 2022 as 2021 suffered from the chip shortage. GM Financial became the company's captive finance arm in October 2010 via the purchase of AmeriCredit.
Read more on GM →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
